Cooley advised Neurocrine Biosciences on its strategic partnership agreement with Takeda to develop and commercialize potential therapies in Takeda’s early- to mid-stage pipeline for psychiatric disorders. The partnership will enhance Neurocrine’s growing pipeline of treatments and strengthen the company’s position as a leading neuroscience-focused biopharmaceutical company.
Neurocrine will develop and commercialize all pipeline compounds included in the collaboration. Under the terms of the agreement, Neurocrine will pay Takeda $120 million in upfront cash and up to $495 million in development milestones, $1.4 billion in commercial milestones and double-digit royalties on net sales.
